
Aranidipine
CAS No. 86780-90-7
Aranidipine( MPC1304 )
Catalog No. M20129 CAS No. 86780-90-7
Aranidipine (MPC1304) is a calcium channel antagonist with potent and long-lasting antihypertensive effects.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 42 | In Stock |
![]() ![]() |
10MG | 76 | In Stock |
![]() ![]() |
25MG | 138 | In Stock |
![]() ![]() |
50MG | 233 | In Stock |
![]() ![]() |
100MG | 393 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameAranidipine
-
NoteResearch use only, not for human use.
-
Brief DescriptionAranidipine (MPC1304) is a calcium channel antagonist with potent and long-lasting antihypertensive effects.
-
DescriptionAranidipine (MPC1304) is a calcium channel antagonist with potent and long-lasting antihypertensive effects.(In Vivo):Aranidipine (MPC-1304) is a new Ca2+ channel antagonist in spontaneously hypertensive rats. Following oral administration of Aranidipine at doses of 3 and 10 mg/kg to spontaneously hypertensive rats (SHR), there are significant decreases in Bmax values for specific [3H](+)-PN 200-110 binding to myocardial membranes compared to the control values. The Bmax values at 1 h (3 mg/kg), 1 and 6 h (10 mg/kg) are significantly decreased (47.7, 48.9 and 25.8%, respectively) compared to the control values. The effect is greatest at 1 h and decreases with time. The Bmax values at 6 h (3 mg/kg) and 12 or 24 h (10 mg/kg) after the oral administration of Aranidipine are not significantly different from the control values, suggesting the disappearance of the effect of Aranidipine. The Kd values for myocardial [3H](+)-PN 200-110 binding are unaltered by oral administration of Aranidipine.
-
In Vitro——
-
In VivoAranidipine (MPC-1304) is a new Ca2+ channel antagonist in spontaneously hypertensive rats. Following oral administration of Aranidipine at doses of 3 and 10 mg/kg to spontaneously hypertensive rats (SHR), there are significant decreases in Bmax values for specific [3H](+)-PN 200-110 binding to myocardial membranes compared to the control values. The Bmax values at 1 h (3 mg/kg), 1 and 6 h (10 mg/kg) are significantly decreased (47.7, 48.9 and 25.8%, respectively) compared to the control values. The effect is greatest at 1 h and decreases with time. The Bmax values at 6 h (3 mg/kg) and 12 or 24 h (10 mg/kg) after the oral administration of Aranidipine are not significantly different from the control values, suggesting the disappearance of the effect of Aranidipine. The Kd values for myocardial [3H](+)-PN 200-110 binding are unaltered by oral administration of Aranidipine.
-
SynonymsMPC1304
-
PathwayGPCR/G Protein
-
TargetCalcium Channel
-
RecptorCalcium Channel
-
Research AreaCardiovascular Disease
-
IndicationAngina pectoris and high blood pressure
Chemical Information
-
CAS Number86780-90-7
-
Formula Weight388.37
-
Molecular FormulaC19H20N2O7
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)=O
-
Chemical Name(+-)-Acetonyl methyl 14-dihydro-26-dimethyl-4-(o-nitrophenyl)-35-pyridinedicarboxylate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Masumiya H et al. Inhibition of T-type and L-type Ca(2+) currents by aranidipine a novel dihydropyridine Ca(2+) antagonist. Pharmacology. 2000 Aug;61(2):57-61.
molnova catalog



related products
-
Levetiracetam
Levetiracetam(UCB L059) is a novel anticonvulsant with antihyperalgesic efficacy in inflammatory pain.
-
ML335
ML335 is a selective activator of both TREK-1 and TREK-2.
-
Caldaret HCl
Caldaret HCl is an intracellular Ca2+ modulator that regulates calcium homeostasis at the sarcoplasmic reticulum and cell membrane, and can be used to study acute myocardial infarction and heart failure.